10.1111/j.1474-9726.2011.00754.x
10.1111/j.1474-9726.2011.00754.x · doi-reference
10.1038/s41556-018-0136-x
10.1038/s41556-018-0136-x · doi-reference
Methods of induced pluripotent stem cells for clinical application
10.4252/wjsc.v7.i1.116 · doi-reference
10.1038/nbt1374
10.1038/nbt1374 · doi-reference
10.1016/j.stem.2007.12.001
10.1016/j.stem.2007.12.001 · doi-reference
10.1007/s00005-016-0385-y
10.1007/s00005-016-0385-y · doi-reference
Human embryonic stem cells: research, ethics and policy
10.1093/humrep/deg143 · doi-reference
10.1038/nbt.3081
10.1038/nbt.3081 · doi-reference
10.1038/nbt.3471
10.1038/nbt.3471 · doi-reference
10.1038/s41589-019-0432-1
10.1038/s41589-019-0432-1 · doi-reference
10.1016/j.devcel.2018.04.021
10.1016/j.devcel.2018.04.021 · doi-reference
CRISPR/Cas9-mediated precise genome modification by a long ssDNA template in zebrafish
10.1186/s12864-020-6493-4 · doi-reference
Highly efficient genome editing for single-base substitutions using optimized ssODNs with Cas9-RNPs
10.1038/s41598-019-41121-4 · doi-reference
10.1038/nmeth.2857
10.1038/nmeth.2857 · doi-reference
10.1038/nature16526
10.1038/nature16526 · doi-reference
10.1158/0008-5472.can-11-0359
10.1158/0008-5472.can-11-0359 · doi-reference
10.1038/nbt.2678
10.1038/nbt.2678 · doi-reference
10.1089/biores.2019.0046
10.1089/biores.2019.0046 · doi-reference
The CRISPR-baby scandal: what's next for human gene-editing
10.1038/d41586-019-00673-1 · doi-reference
10.1038/s41591-018-0327-9
10.1038/s41591-018-0327-9 · doi-reference
In vivo applications of CRISPR-based genome editing in the retina
10.3389/fcell.2018.00053 · doi-reference
10.1038/d41586-020-00655-8
10.1038/d41586-020-00655-8 · doi-reference
CRISPR-engineered T cells in patients with refractory cancer
10.1126/science.aba7365 · doi-reference
10.1182/blood-2013-03-478255
10.1182/blood-2013-03-478255 · doi-reference
Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition
10.1158/1078-0432.ccr-16-1300 · doi-reference
10.1073/pnas.1512503112
10.1073/pnas.1512503112 · doi-reference
10.18632/oncotarget.15218
10.18632/oncotarget.15218 · doi-reference
10.1038/nature21405
10.1038/nature21405 · doi-reference
10.1038/s12276-018-0190-2
10.1038/s12276-018-0190-2 · doi-reference
10.1038/nbt.3860
10.1038/nbt.3860 · doi-reference
Toward a universal solution: editing compatibility into pluripotent stem cells
10.1016/j.stem.2019.03.003 · doi-reference
10.1016/j.stem.2019.02.005
10.1016/j.stem.2019.02.005 · doi-reference
10.1038/nri1570
10.1038/nri1570 · doi-reference
10.1002/stem.3269
10.1002/stem.3269 · doi-reference
10.1073/pnas.1902566116
10.1073/pnas.1902566116 · doi-reference
Generation and characterization of HLA-universal platelets derived from induced pluripotent stem cells
10.1038/s41598-020-65577-x · doi-reference
Human leukocyte antigen class I and II knockout human induced pluripotent stem cell-derived cells: universal donor for cell therapy
10.1161/jaha.118.010239 · doi-reference
10.1038/s41587-019-0016-3
10.1038/s41587-019-0016-3 · doi-reference
10.5966/sctm.2015-0049
10.5966/sctm.2015-0049 · doi-reference
10.1038/mt.2013.59
10.1038/mt.2013.59 · doi-reference
